ACADIA Pharmaceuticals Company Profile (NASDAQ:ACAD)

About ACADIA Pharmaceuticals (NASDAQ:ACAD)

ACADIA Pharmaceuticals logoACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PD Psychosis). NUPLAZID is a selective serotonin inverse agonist (SSIA), preferentially targeting 5-HT2A receptors. The Company is conducting a Phase II trial, referred to as the SERENE Study, designed to examine the efficacy and safety of pimavanserin as a treatment for Alzheimer's disease (AD) Agitation. It is also conducting a Phase III, six-week, randomized, double-blind, placebo-controlled, multi-center, outpatient study, referred to as the ENHANCE-1 study, designed to examine the use of pimavanserin in patients with schizophrenia.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ACAD
  • CUSIP: N/A
  • Web:
  • Market Cap: $3.42 billion
  • Outstanding Shares: 122,046,000
Average Prices:
  • 50 Day Moving Avg: $32.00
  • 200 Day Moving Avg: $31.95
  • 52 Week Range: $20.68 - $42.49
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -13.73
  • P/E Growth: -0.33
Sales & Book Value:
  • Annual Revenue: $32.61 million
  • Price / Sales: 104.83
  • Book Value: $3.75 per share
  • Price / Book: 7.47
  • EBIDTA: ($309,030,000.00)
  • Net Margins: -4,427.79%
  • Return on Equity: -58.46%
  • Return on Assets: -54.70%
  • Current Ratio: 15.42%
  • Quick Ratio: 15.31%
  • Average Volume: 1.64 million shs.
  • Beta: 3.94
  • Short Ratio: 10.1

Frequently Asked Questions for ACADIA Pharmaceuticals (NASDAQ:ACAD)

What is ACADIA Pharmaceuticals' stock symbol?

ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."

How were ACADIA Pharmaceuticals' earnings last quarter?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) released its earnings results on Tuesday, May, 9th. The company reported ($0.72) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.01. The company had revenue of $15.30 million for the quarter, compared to analyst estimates of $15.17 million. ACADIA Pharmaceuticals had a negative return on equity of 58.46% and a negative net margin of 4,427.79%. During the same period in the prior year, the firm posted ($0.45) EPS. View ACADIA Pharmaceuticals' Earnings History.

Where is ACADIA Pharmaceuticals' stock going? Where will ACADIA Pharmaceuticals' stock price be in 2017?

14 brokerages have issued 12-month target prices for ACADIA Pharmaceuticals' shares. Their forecasts range from $25.00 to $60.00. On average, they anticipate ACADIA Pharmaceuticals' share price to reach $43.00 in the next year. View Analyst Ratings for ACADIA Pharmaceuticals.

What are analysts saying about ACADIA Pharmaceuticals stock?

Here are some recent quotes from research analysts about ACADIA Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia. " (5/12/2017)
  • 2. Needham & Company LLC analysts commented, "Acadia reported $11.9M in 4Q16 Nuplazid sales, above our $9.0M estimate. Mgmt noted steady growth in number of prescribers, repeat prescribers, and new patients. Company also announced plan to expand sales force by 20 reps to address long-term care opportunity. There are no immediate plans to provide 2017 sales guidance. We believe stock is attractive given Nuplazid launch trajectory and likelihood for label expansion in long-term. Stock likely to be driven by sales in 2017 and Phase 2/3 results in other indications in 2018/ 2019. Acadia may be an attractive M&A target. BUY." (3/1/2017)

Who are some of ACADIA Pharmaceuticals' key competitors?

Who owns ACADIA Pharmaceuticals stock?

ACADIA Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BAKER BROS. ADVISORS LP (22.10%), FMR LLC (0.00%), Vanguard Group Inc. (0.00%), BlackRock Inc. (0.00%), OppenheimerFunds Inc. (0.00%) and Janus Capital Management LLC (2.82%). Company insiders that own ACADIA Pharmaceuticals stock include Bros Advisors Lp Baker, Edmund Harrigan, Glenn Baity, Leslie L Iversen, LP 14159 and Terrence O Moore. View Institutional Ownership Trends for ACADIA Pharmaceuticals.

Who sold ACADIA Pharmaceuticals stock? Who is selling ACADIA Pharmaceuticals stock?

ACADIA Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., JPMorgan Chase & Co., First Trust Advisors LP, State Street Corp, UBS Group AG, SG Americas Securities LLC, Pictet Asset Management Ltd. and Columbus Circle Investors. Company insiders that have sold ACADIA Pharmaceuticals stock in the last year include Glenn Baity and Terrence O Moore. View Insider Buying and Selling for ACADIA Pharmaceuticals.

Who bought ACADIA Pharmaceuticals stock? Who is buying ACADIA Pharmaceuticals stock?

ACADIA Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Elliott Management Corp, Point72 Asset Management L.P., Ameriprise Financial Inc., Vanguard Group Inc., Frontier Capital Management Co. LLC, Westfield Capital Management Co. LP and Edmond DE Rothschild Holding S.A.. Company insiders that have bought ACADIA Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker, Edmund Harrigan and LP 14159. View Insider Buying and Selling for ACADIA Pharmaceuticals.

How do I buy ACADIA Pharmaceuticals stock?

Shares of ACADIA Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of ACADIA Pharmaceuticals stock cost?

One share of ACADIA Pharmaceuticals stock can currently be purchased for approximately $28.01.

Analyst Ratings

Consensus Ratings for ACADIA Pharmaceuticals (NASDAQ:ACAD) (?)
Ratings Breakdown: 4 Hold Ratings, 10 Buy Ratings
Consensus Rating:Buy (Score: 2.71)
Consensus Price Target: $43.00 (53.52% upside)

Analysts' Ratings History for ACADIA Pharmaceuticals (NASDAQ:ACAD)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/22/2017Rodman & RenshawReiterated RatingBuy$60.00LowView Rating Details
5/10/2017HC WainwrightReiterated RatingBuyLowView Rating Details
4/12/2017Jefferies Group LLCReiterated RatingBuy$47.00LowView Rating Details
4/5/2017Needham & Company LLCReiterated RatingBuy$49.00LowView Rating Details
2/7/2017Piper Jaffray CompaniesReiterated RatingOverweight$44.00N/AView Rating Details
2/2/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuy -> Buy$49.00 -> $48.00N/AView Rating Details
1/24/2017Cowen and CompanyReiterated RatingOutperform$42.00N/AView Rating Details
1/11/2017JPMorgan Chase & Co.Reiterated RatingBuyN/AView Rating Details
12/28/2016Leerink SwannReiterated RatingMarket Perform$29.00N/AView Rating Details
11/11/2016Goldman Sachs Group IncInitiated CoverageNeutral$28.00N/AView Rating Details
11/8/2016Bank of America CorpUpgradeNeutral -> Buy$35.00N/AView Rating Details
10/19/2016Roth CapitalReiterated RatingNeutral$25.00N/AView Rating Details
8/10/2016JMP SecuritiesReiterated RatingBuy$45.00N/AView Rating Details
8/5/2016AegisDowngradeBuy -> Hold$54.00 -> $41.00N/AView Rating Details
(Data available from 5/22/2015 forward)


Earnings History for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Earnings by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Earnings History by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.73)($0.72)$15.17 million$15.30 millionViewListenView Earnings Details
2/28/2017Q416($0.65)($0.65)$9.05 million$12.00 millionViewListenView Earnings Details
11/7/2016Q316($0.56)($0.61)$2.90 million$5.30 millionViewListenView Earnings Details
8/4/2016Q216($0.49)($0.63)$0.71 million$0.97 millionViewListenView Earnings Details
5/5/2016Q116($0.42)($0.45)$0.22 millionViewListenView Earnings Details
2/29/2016Q415($0.38)($0.45)$0.02 millionViewListenView Earnings Details
11/5/2015Q315($0.40)($0.39)$0.05 million$0.04 millionViewListenView Earnings Details
8/6/2015Q215($0.33)($0.39)$0.06 millionViewListenView Earnings Details
5/7/2015Q115($0.25)($0.40)$0.09 millionViewListenView Earnings Details
2/26/2015Q414($0.26)($0.28)$0.08 million$0.05 millionViewListenView Earnings Details
11/10/2014Q3($0.12)($0.25)$0.02 millionViewListenView Earnings Details
8/5/2014Q2($0.17)($0.22)$0.10 million$0.03 millionViewListenView Earnings Details
5/6/2014Q1($0.13)($0.19)$0.50 million$0.03 millionViewListenView Earnings Details
2/27/2014Q4($0.14)($0.13)ViewListenView Earnings Details
8/6/2013Q2 2013($0.09)($0.11)$0.45 million$451.00 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.08)($0.08)$0.45 million$0.42 millionViewListenView Earnings Details
11/5/2012Q312($0.09)($0.04)$1.90 million$3.50 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for ACADIA Pharmaceuticals (NASDAQ:ACAD)
2017 EPS Consensus Estimate: ($2.37)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.75)($0.53)($0.64)
Q2 20172($0.71)($0.48)($0.60)
Q3 20172($0.72)($0.44)($0.58)
Q4 20172($0.71)($0.39)($0.55)
(Data provided by Zacks Investment Research)


Dividend History for ACADIA Pharmaceuticals (NASDAQ:ACAD)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Insider Ownership Percentage: 21.65%
Institutional Ownership Percentage: 98.25%
Insider Trades by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Institutional Ownership by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Insider Trades by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/16/2017Terrence O. MooreEVPSell157,540$39.77$6,265,365.80View SEC Filing  
12/27/2016Glenn BaityEVPSell9,800$30.46$298,508.00View SEC Filing  
12/20/2016Glenn BaityEVPSell10,000$30.00$300,000.00View SEC Filing  
8/16/2016Edmund HarriganDirectorBuy1,000$32.97$32,970.00View SEC Filing  
8/10/2016Bros. Advisors Lp BakerDirectorBuy1,303,030$33.00$42,999,990.00View SEC Filing  
7/12/2016Glenn BaityEVPSell16,000$35.00$560,000.00View SEC Filing  
7/11/2016Glenn BaityEVPSell4,057$35.00$141,995.00View SEC Filing  
4/18/2016Leslie L IversenDirectorSell33,697$33.53$1,129,860.41View SEC Filing  
4/1/2016Bros. Advisors Lp BakerDirectorBuy1,449,090$27.08$39,241,357.20View SEC Filing  
1/7/2016L.P. 14159DirectorBuy2,586,206$29.00$74,999,974.00View SEC Filing  
11/11/2015Leslie L. IversenDirectorSell30,000$36.01$1,080,300.00View SEC Filing  
1/15/2015Michael T BorerDirectorSell27,973$33.02$923,668.46View SEC Filing  
1/14/2015Uli HacksellCEOSell30,000$33.98$1,019,400.00View SEC Filing  
12/15/2014Mary Ann GrayDirectorSell12,250$31.74$388,815.00View SEC Filing  
12/15/2014Uli HacksellCEOSell30,000$31.00$930,000.00View SEC Filing  
11/26/2014Michael T BorerDirectorSell15,000$30.05$450,750.00View SEC Filing  
11/26/2014Roger MillsCMOSell25,000$30.09$752,250.00View SEC Filing  
11/24/2014Uli HacksellCEOSell30,000$29.28$878,400.00View SEC Filing  
11/21/2014William Mcdowall WellsDirectorSell5,810$29.00$168,490.00View SEC Filing  
10/8/2014Uli HacksellCEOSell30,000$24.15$724,500.00View SEC Filing  
9/15/2014Laura BregeDirectorSell10,000$28.07$280,700.00View SEC Filing  
9/12/2014William Mcdowall WellsDirectorSell9,190$29.15$267,888.50View SEC Filing  
9/10/2014Uli HacksellCEOSell30,000$27.36$820,800.00View SEC Filing  
8/15/2014Uli HacksellCEOSell15,000$22.89$343,350.00View SEC Filing  
7/14/2014Uli HacksellCEOSell20,000$22.22$444,400.00View SEC Filing  
6/16/2014Uli HacksellCEOSell20,000$23.10$462,000.00View SEC Filing  
6/9/2014William Mcdowall WellsDirectorSell15,000$23.03$345,450.00View SEC Filing  
5/1/2014Torsten RasmussenDirectorSell32,857$20.03$658,125.71View SEC Filing  
4/15/2014Uli HacksellCEOSell25,000$17.75$443,750.00View SEC Filing  
4/4/2014Thomas AasenCFOSell15,000$22.48$337,200.00View SEC Filing  
4/4/2014Torsten RasmussenDirectorSell30,000$21.98$659,400.00View SEC Filing  
3/5/2014Bros. Advisors Lp BakerDirectorBuy526,316$28.50$15,000,006.00View SEC Filing  
2/26/2014Glenn BaityVPSell42,000$30.28$1,271,760.00View SEC Filing  
11/1/2013Torsten RasmussenDirectorSell37,692$23.00$866,916.00View SEC Filing  
11/1/2013Uli HacksellCEOSell15,000$23.24$348,600.00View SEC Filing  
10/10/2013Laura BregeDirectorSell10,000$21.63$216,300.00View SEC Filing  
10/1/2013Thomas H AasenCFOSell30,000$27.87$836,100.00View SEC Filing  
9/20/2013Roger MillsCMOSell35,965$25.01$899,484.65View SEC Filing  
9/12/2013Lester Ph KaplanDirectorSell66,356$22.90$1,519,552.40View SEC Filing  
9/10/2013Laura BregeDirectorSell46,153$22.80$1,052,288.40View SEC Filing  
9/3/2013Torsten RasmussenDirectorSell40,000$20.28$811,200.00View SEC Filing  
8/26/2013Mary Ann GrayDirectorSell15,000$20.68$310,200.00View SEC Filing  
8/13/2013Thomas AasenCFOSell60,000$20.15$1,209,000.00View SEC Filing  
8/13/2013Uli HacksellCEOSell52,771$20.14$1,062,807.94View SEC Filing  
6/5/2013Felix BakerDirectorBuy2,340,314$14.34$33,560,102.76View SEC Filing  
5/15/2013Felix BakerDirectorBuy1,993,000$12.50$24,912,500.00View SEC Filing  
4/12/2013Glenn BaityVPSell60,000$12.42$745,200.00View SEC Filing  
4/11/2013Thomas H AasenCFOSell40,000$11.06$442,400.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Latest Headlines for ACADIA Pharmaceuticals (NASDAQ:ACAD)
DateHeadline logoACADIA Pharmaceuticals Inc. (ACAD) Receives Average Recommendation of "Buy" from Analysts - May 22 at 12:25 PM logoACADIA Pharmaceuticals Inc. (ACAD) Stock Rating Reaffirmed by Rodman & Renshaw - May 22 at 10:54 AM logoLongwood Capital Partners LLC Buys ACADIA Pharmaceuticals Inc, Viveve Medical Inc, Biocryst ... - Nasdaq - May 16 at 5:40 AM logoACADIA Pharmaceuticals Inc. (ACAD) Upgraded to Hold by Zacks Investment Research - May 12 at 10:06 PM logoAcadia Pharmaceuticals: Patience Will Be Rewarded - Seeking Alpha - May 12 at 3:34 PM logoACADIA Pharmaceuticals Inc. (ACAD) to Post Q2 2017 Earnings of ($0.71) Per Share, Leerink Swann Forecasts - May 12 at 10:58 AM logoACADIA Pharmaceuticals Inc. (ACAD) Rating Reiterated by HC Wainwright - May 11 at 7:36 AM logoEdited Transcript of ACAD earnings conference call or presentation 9-May-17 9:00pm GMT - May 10 at 8:27 PM logoOversold Conditions For Acadia Pharmaceuticals (ACAD) - Nasdaq - May 10 at 3:25 PM logoThe Acadia Sell-off Is Overdone - May 10 at 3:25 PM logoACADIA Pharmaceuticals Inc. (ACAD) Expected to Announce Quarterly Sales of $18.39 Million - May 10 at 11:54 AM logoACADIA Pharmaceuticals Inc. (ACAD) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS - May 10 at 12:36 AM logoBRIEF-Acadia Pharmaceuticals reports Q1 revenue $15.3 million - May 9 at 8:19 PM logo10-Q: ACADIA PHARMACEUTICALS INC - May 9 at 8:19 PM logoACADIA Pharmaceuticals Reports First Quarter 2017 Financial Results - May 9 at 8:19 PM logoAcadia reports 1Q loss - May 9 at 6:01 PM logoInvestor Network: ACADIA Pharmaceuticals Inc. to Host Earnings Call - May 9 at 3:17 PM logoACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference on May 16, 2017 - May 8 at 11:27 AM logoZacks: Analysts Expect ACADIA Pharmaceuticals Inc. (ACAD) to Announce -$0.73 EPS - May 8 at 9:56 AM logoACADIA Pharmaceuticals to Announce First Quarter 2017 Financial Results on May 9, 2017 - Yahoo Finance - May 4 at 3:18 PM logoWhat to do when your biotechnology stock gets hit by takeover rumors - May 4 at 3:18 PM logoWhat's in the Cards for ACADIA (ACAD) this Earnings Season? - May 4 at 1:22 AM logoACADIA Pharmaceuticals to Announce First Quarter 2017 Financial Results on May 9, 2017 - Business Wire (press release) - May 2 at 3:21 PM logoACADIA Pharmaceuticals to Announce First Quarter 2017 Financial Results on May 9, 2017 - May 2 at 3:21 PM logoWhat's in the Cards for ACADIA (ACAD) this Earnings Season? - May 2 at 3:21 PM logoACADIA Pharmaceuticals (ACAD) Getting Somewhat Positive Media Coverage, Study Shows - May 2 at 7:48 AM logoETFs with exposure to ACADIA Pharmaceuticals, Inc. : May 1, 2017 - May 2 at 5:40 AM logoACADIA Pharmaceuticals Inc. (ACAD) Set to Announce Earnings on Wednesday - May 1 at 9:17 AM logoACADIA Pharmaceuticals (ACAD) Getting Somewhat Negative News Coverage, Report Finds - April 29 at 8:42 AM logoAcadia Pharmaceuticals May Just Be the Best Long-Term Play on the Alzheimer's Disease Treatment Market - Motley Fool - April 27 at 3:36 PM logoSomewhat Favorable News Coverage Likely to Impact ACADIA Pharmaceuticals (ACAD) Share Price - April 26 at 9:19 AM logoAcadia Pharmaceuticals May Just Be the Best Long-Term Play on the Alzheimer's Disease Treatment Market - April 25 at 3:17 PM logoACADIA Pharmaceuticals Inc. (ACAD) Given Average Rating of "Buy" by Analysts - April 25 at 12:33 PM logoHow These Biotech Stocks are Faring? -- ACADIA Pharma, Alexion Pharma, TG Therapeutics, and Esperion ... - PR Newswire (press release) - April 24 at 3:18 PM logoBiotech M&A Plunges as Trump Attacks Drug Companies - April 24 at 11:14 AM logoSomewhat Critical News Coverage Very Likely to Affect ACADIA Pharmaceuticals (ACAD) Stock Price - April 23 at 7:35 AM logoACADIA Pharmaceuticals (ACAD) Earns Media Sentiment Score of -0.06 - April 20 at 7:31 AM logoETFs with exposure to ACADIA Pharmaceuticals, Inc. : April 19, 2017 - April 19 at 3:15 PM logo Analysts Expect ACADIA Pharmaceuticals Inc. (ACAD) Will Announce Quarterly Sales of $13.82 Million - April 19 at 12:48 PM logoJefferies Group LLC Reiterates Buy Rating for ACADIA Pharmaceuticals Inc. (ACAD) - April 18 at 7:25 AM logoACADIA Pharmaceuticals (ACAD) Given Daily News Impact Score of 0.12 - April 17 at 10:05 AM logo Analysts Expect ACADIA Pharmaceuticals Inc. (ACAD) Will Announce Earnings of -$0.73 Per Share - April 17 at 8:38 AM logoACADIA Pharmaceuticals Inc. (ACAD) Upgraded at Zacks Investment Research - April 14 at 10:35 PM logoACADIA Pharmaceuticals (ACAD) Earning Somewhat Positive Media Coverage, Analysis Finds - April 14 at 1:49 PM logoShort Interest in ACADIA Pharmaceuticals Inc. (ACAD) Decreases By 3.7% - April 13 at 7:22 AM logoJefferies Group LLC Reiterates "Buy" Rating for ACADIA Pharmaceuticals Inc. (ACAD) - April 12 at 3:15 PM logoACADIA Pharmaceuticals (ACAD) Presents At 16th Annual Needham Healthcare Conference - Slideshow - April 7 at 3:17 PM logoAcadia Pharmaceuticals Becomes Oversold (ACAD) - - Nasdaq - April 7 at 5:34 AM logoETFs with exposure to ACADIA Pharmaceuticals, Inc. : April 5, 2017 - April 7 at 5:34 AM logoACADIA Pharmaceuticals Inc. (ACAD) Upgraded by Zacks Investment Research to "Hold" - April 5 at 10:31 PM


ACADIA Pharmaceuticals (ACAD) Chart for Monday, May, 22, 2017

This page was last updated on 5/22/2017 by Staff